In its most recent 13F filing with the SEC, Commerzbank Aktiengesellschaft FI disclosed a 30.5% reduction in its position in AbbVie Inc., selling 39,586 shares and ending the period with 90,102 shares. At the time of reporting, those holdings were valued at approximately $20.9 million. This move contrasts with several other major institutions that either increased or initiated stakes in AbbVie during the same period. Notably, Norges Bank established a new position valued around $4.29 billion, while Vanguard Group added 3.38 million shares, bringing its total stake to approximately 177.3 million shares. DZ BANK AG and Raymond James Financial also boosted their holdings by 169.3% and 41.8%, respectively, underscoring continued confidence from large custodial and advisory firms despite Commerzbank’s reduction.

AbbVie reported third-quarter results that surpassed consensus expectations, delivering $15.78 billion in revenue, up 9.1% year-over-year, and earnings per share of $1.86, beating estimates by $0.09. The company’s net margin stood at 4.0%, while return on equity registered an extraordinary 3,216.5%, driven by its specialty immunology and oncology franchises. Management set Q4 2025 guidance in a range of $3.32 to $3.36 per share, and analysts currently project full-year earnings of approximately $12.31 per share. These figures reinforce AbbVie’s ability to sustain growth through its diversified pipeline and established blockbuster therapies despite patent expirations in certain product lines.

AbbVie announced a quarterly dividend of $1.73 per share, payable February 17, with a record date of January 16. This represents an annualized payout of $6.92 per share, up from $6.56, and results in a current yield of roughly 3.2%. The dividend payout ratio has climbed to 524%, reflecting the company’s commitment to returning capital even as earnings fluctuate. Over the past decade, AbbVie has maintained uninterrupted annual dividend growth, cementing its status among the sector’s most reliable income generators and signaling management’s confidence in future free cash flow generation.